SIRIUS Direct

Study of:
Siroliums-eluting Bx Velocity™ stent; sponsored by Cordis, a Johnson and Johnson Company

Drug coated or drug eluting stents are designed to block excessive cell growth that can cause restenosis (renarrowing of the artery) after stent implantation. Restenosis can occur in about 25% of the patients who receive a coronary artery stent. Drug coated stents are currently being studied to reduce the growth of scar tissue in the coronary artery.

The main objective of The SIRIUS Direct study is to assess the safety and effectiveness of outcomes following the use of the Siroliums-eluting Bx Velocity™ stent when direct stenting (implanting a stent without doing angioplasty first). It also hopes to demonstrate that direct stenting with the Sirolimus-eluting Bx Velocity™ stent is no less effective than those individuals treated with balloon angioplasty prior to stent placement. Patients will be followed at 30-days, 3, 6, 9 and 12 months post procedure with a repeat angiogram done at 8 months.

• Michael R. Mooney, MD, FACC

• M. Nicholas Burke, MD
• Ivan J. Chavez, MD, FACC
• Timothy D. Henry, MD, FACC
• John R. Lesser, MD, FACC
• Daniel Lips, MD, FACC
• James D. Madison, MD, FACC
• Wesley R. Pedersen, MD, FACC
• Anil K. Poulose, MD, FACC
• Jay H. Traverse, MD, FACC, FAHA
• Yale Wang, MD, FACC, FSCAI

• Gretchen Peichel, RN

For more information about the interventional cardiology research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.